Table S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules

作者：Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Jürgen Ramharter, Rolf Grempler, Jens Quant, Joerg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, S. R. Otto, Christian Mandl, Guido Boehmelt, Darryl B. McConnell, Norbert Kraut, Patrizia Sini · 年份：2026 · DOI：10.1158/1535-7163.32715136 · 研究领域：Cancer-related Molecular Pathways、Hedgehog Signaling Pathway Studies、Retinoids in leukemia and cellular processes

<p>Brigimadlin PK parameters in SJSA-1 osteosarcoma MDM2-amplified xenograft model.</p>